Immatics (NasdaqCM:IMTX) reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel (IMA203), its lead cancer immunotherapy candidate. The company has set timelines for the final analysis of ...

Phase shift analysis remains a cornerstone of modern scattering theory, underpinning our understanding of how particles interact under various potential fields. By examining the phase differences ...

DJT was exceptional last week: Up over 50% on 200M share trading volume. The stock is now well above its $12.50 low, the $15 major barrier, and the $17.50 January starting point. It has now returned ...

Determining phase stability and evolution at elevated temperatures, as well as identifying the formation of new phases or the reaction temperature and pathway of a known solid-state reaction is a ...

IgA nephropathy, the most common primary glomerulopathy worldwide, is a kidney disorder of B-cell origin characterized by mesangial accumulation of IgA-containing immune complexes. In at least 50% of ...

Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the ...

Patients with advanced clear cell RCC whose disease progressed after 1-3 prior systemic therapies (including an anti–PD- [L]1 therapy) were randomly assigned 1:1 to belzutifan 200 mg or 120 mg daily: ...